Real-world data gets high marks for feasibility in lung cancer research: A cross-industry collaboration is advancing RWD
The real world is an unpredictable place. It can be messy and confusing, full of challenges and uncertainties that have to be overcome before we can move forward with confidence and clarity toward our goals. The same is true of the real-world data (RWD) generated by clinicians, health plans, medical devices, patients, and more. Before […]
Light the Night: Bringing hope to patients during Blood Cancer Awareness Month
September is Blood Cancer Awareness Month, a time to bring extra attention to the more than 1.6 million people living with leukemia, lymphoma, myeloma, and other hematological cancers. These cancers can strike people of all ages, including children and young adults. Blood cancers account for almost 10% of all new cancer diagnoses in the US […]
COTA and Panalgo Q&A
COTA Spokesperson: C.K. Wang, Chief Medical Officer Panalgo Spokesperson: Meg Richards, PhD, MPH, Executive Director of Scientific Strategy Abbreviated answers Q: What is the value of real-world data for accurate healthcare analytics – what can be learned from high-quality electronic health record data? Meg: Real-world data (RWD), particularly those derived from high-quality electronic health records […]
The promise of clinicogenomic data for breakthrough cancer drug development
Life science companies have many different data types at their disposal to support research and development, from established literature and clinical trial evidence to a growing range of real-world data (RWD) assets that are opening up new opportunities every day. Among these novel datasets is clinicogenomic data: a mashup of longitudinal, deidentified clinical information with […]
Breaking through the barriers to expand real-world data use across pharma
Pharma companies are engaged in a never-ending quest to get more effective, safer therapies to patients in a faster and more accessible manner. They are constantly looking for ways to innovate, whether that’s exploring new drug classes for rare diseases or creatively connecting with audiences to enhance equity across communities in need. But there are […]
RWD and GenAI: How technology’s new power couple will revolutionize life sciences
Generative AI (GenAI) is quickly proving itself to be one of the most transformative technologies of our time with its ability to synthesize data and create new content as well as (or sometimes better than) its human creators. But GenAI needs a powerful partner if it’s going to wow users with high-quality, trustworthy, bias-free results: […]
COTA and Texas Oncology Collaborate to Advance AI-Enabled Precision Medicine
New York — COTA, Inc., in collaboration with Texas Oncology’s Precision Health Informatics, LLC (PHI), announces an innovative collaboration aimed at revolutionizing precision medicine across Texas Oncology’s community cancer centers. Leveraging COTA’s AI-powered curation engine, CAILIN™, this collaboration will transform fragmented healthcare data into actionable insights. Unlocking Insights from Electronic Health Records (EHRs) Electronic health records […]
COTA and Hackensack Meridian Health at ASCO 2024
Compared to information from clinical trials, real-world data (RWD) provides oncologists and cancer researchers with data on how diverse groups of patients are treated in current clinical practice. Researchers from Hackensack Meridian Health and COTA teamed up to analyze real-world treatment outcomes for people with multiple myeloma – a type of blood cancer. The findings, […]
Introducing CAILIN: The Latest Development from COTA’s AI Lab
At COTA, we know that high-quality oncology real-world data (RWD) holds the keys to the next breakthrough in cancer care. Through our work with life sciences partners, oncologists, and hospitals across the U.S., we’ve seen firsthand how data can power discoveries about new treatments and inform the right steps in care for patients. We also […]
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
COTA, PreciseDx and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence (AI) -enabled PreciseBreast™ (PDxBr) test that predicts the likelihood of invasive breast cancer (IBC) recurrence.
